Government Expands Cancer Medicine Price Controls
Ministry of Chemicals and Fertilizers - Department of Pharmaceuticals · Health · Posted 08 OCT 2026 10:04PM
What happened
The government approved a cap on trade margins for non-scheduled anti-cancer drugs at 30% of the Maximum Retail Price (MRP), a move expected to reduce medicine prices by up to 70% and save cancer patients ₹2,500 crore annually. An expert committee under the DGHS will finalize the covered medicines, and the National Pharmaceutical Pricing Authority (NPPA) will issue the notification.
Why it matters for UPSC
This decision highlights government interventions in healthcare pricing and regulation of pharmaceutical trade margins to reduce out-of-pocket expenditure, directly illustrating issues related to health policy and welfare under the social justice and governance syllabus.
Key objectives
- Capped margins on non-scheduled anti-cancer drugs to 30% of the Maximum Retail Price (MRP).
- Expected to reduce medicine prices by up to 70% and save cancer patients ₹2,500 crore annually.
- Manufacturers required to maintain their current production levels to ensure continued availability.